Loading...

Pharmaceutical Continuous Manufacturing Market by Product (Integrated Continuous Systems, Semicontinuous Systems, and Control & Software), Application (Final Drug Product Manufacturing and API Manufacturing), and End User (Pharmaceutical Companies, Contract Manufacturing Organizations, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05875
Pages: 195
Dec 2019 | 2879 Views
 
Author(s) : Sagar Mukhekar , Onkar Sumant
Tables: 104
Charts: 24
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Pharmaceutical Continuous Manufacturing Market

Request Now !

Pharmaceutical Continuous Manufacturing Market Outlook - 2026

The global pharmaceutical continuous manufacturing market was valued at $393 million in 2018, and is projected to reach $855 million by 2026, registering a CAGR of 10.2% from 2019 to 2026. 

Continuous manufacturing is an advanced manufacturing approach with the potential to improve quality and consistency of medications with lower cost. This production line is operated in a continuous flow, with end-to-end integration of manufacturing processes. The pharmaceutical continuous manufacturing market is expected to witness significant growth during the forecast period, due to technological advancements in continuous manufacturing systems and support by the regulatory authorities for adoption of continuous manufacturing systems. However, higher cost of pharmaceutical continuous manufacturing systems impedes the pharmaceutical continuous manufacturing market growth. On the contrary, pharmaceutical manufacturing systems reduce fluctuation in the production, improve yields, lower cost of operation & equipment, which are anticipated to offer remunerative opportunities for market expansion. Recently, in 2019, Caperion launched a next-generation of high accuracy vibratory feeding technology with higher accuracy and quicker product changeover. 

Pharmaceutical Continuous Manufacturing Market

Get more information on this report : Request Sample Pages

 

Global Pharmaceutical Continuous Manufacturing Market Segmentation 

The global pharmaceutical continuous manufacturing market is segmented into product, application, end user, and region. Depending on product, the market is classified into integrated continuous systems, semicontinuous systems, and control & software. The applications covered in the study covered include final drug product manufacturing and API manufacturing. On the basis of end user, the market is categorized into pharmaceutical companies, contract manufacturing organizations, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, and rest of Europe), Asia-Pacific (China, Japan, India, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Segment review 

Depending on product, the integrated continuous systems segment hold the largest pharmaceutical continuous manufacturing market share in 2018, and is anticipated to exhibit significant growth during the forecast period. This is attributed to increase in adoption of integrated continuous manufacturing (ICM) process and availability of ICM systems. 

Pharmaceutical Continuous Manufacturing Market
By Product Type

Your browser does not support the canvas element.

Integrated Continuous Systems is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Depending on application, the final drug product manufacturing segment presently acts as the major revenue generator, and is anticipated to experience significant growth during the forecast period. Rise in number of pharmaceutical companies, technological advancements in continuous manufacturing systems, and rise in demand for pharmaceutical drugs are key drivers of this market. However, API is anticipated to exhibit fastest growth during the forecast period, due to increase in number of R&D activities to develop API with continuous manufacturing system. Furthermore, increase in number of approved drugs produced by continuous processes drives the market growth. For instance, Orkambi by Vertex, Prezista by Janssen, Verzenio by Eli Lilly and Company, and Symdeko by Vertex are produced by continuous manufacturing processes.  

Pharmaceutical Continuous Manufacturing Market
By Application

Your browser does not support the canvas element.

Final Drug Product Manufacturing holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific pharmaceutical continuous manufacturing market 

Asia-Pacific presents lucrative opportunities for the key players operating in the pharmaceutical continuous manufacturing market, due to increase in awareness about advanced pharmaceutical continuous manufacturing systems, rise number of pharmaceutical companies, and increase in demand for continuous manufacturing systems. However, higher cost of pharmaceutical continuous manufacturing systems may hamper the market growth in Asia-Pacific. 

Pharmaceutical Continuous Manufacturing Market
By Geography

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 11.5% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players profiled in this report include Bosch Packaging Technology, Coperion GmbH, GEA Group AG, Gebrüder Lödige Maschinenbau GmbH, Glatt GmbH, Hosokawa Micron Corporation, Korsch AG, L.B. Bohle Maschinen + Verfahren GmbH, Munson Machinery Company, Inc., and Thermo Fisher Scientific Inc. 

Key Benefits for Pharmaceutical Continuous Manufacturing Market:

  • The study provides an in-depth analysis of the pharmaceutical continuous manufacturing market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It provides pharmaceutical continuous manufacturing market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of key players are thoroughly analyzed to understand the competitive outlook and global pharmaceutical continuous manufacturing market growth.

Pharmaceutical Continuous Manufacturing Market Segments:

By Product

  • Integrated Continuous Systems
  • Semicontinuous Systems
  • Control & Software

Application Type

  • Final Drug Product Manufacturing
  • API Manufacturing

End User 

  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China 
    • India 
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia 
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:  INTRODUCTION

1.1.  Report description
1.2.  Key benefits for stakeholders
1.3.  Key market segments

1.3.1.  List of key players profiled in the report

1.4.  Research methodology

1.4.1.  Secondary research
1.4.2.  Primary research
1.4.3.  Analyst tools and models

CHAPTER 2:  EXECUTIVE SUMMARY

2.1.  Key findings of the study
2.2.  CXO perspective

CHAPTER 3:  MARKET OVERVIEW

3.1.  Market definition and scope
3.2.  Key findings

3.2.1.  Top investment pockets
3.2.2.  Market player positioning, 2018

3.3.  Market dynamics

3.3.1.  Drivers

3.3.1.1.  Increase in government support for continuous manufacturing adoption
3.3.1.2.  Advantages offered by continuous manufacturing systems
3.3.1.3.  Surge in adoption of pharmaceutical continuous manufacturing systems

3.3.2.  Restraint

3.3.2.1.  Poor demand in under developed countries

3.3.3.  Opportunities

3.3.3.1.  Growth opportunities in emerging markets

3.3.4.  Impact analysis

CHAPTER 4:  PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT

4.1.  Overview

4.1.1.  Market size and forecast

4.2.  Integrated continuous systems

4.2.1.  Key market trends and opportunities
4.2.2.  Market size and forecast, by region
4.2.3.  Market analysis, by country

4.3.  Semi-continuous systems

4.3.1.  Key market trends and opportunities
4.3.2.  Market size and forecast, by region
4.3.3.  Market analysis, by country

4.4.  Control & software

4.4.1.  Key market trends and opportunities
4.4.2.  Market size and forecast, by region
4.4.3.  Market analysis, by country

CHAPTER 5:  PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION

5.1.  Overview

5.1.1.  Market size and forecast

5.2.  Final drug product manufacturing

5.2.1.  Market size and forecast
5.2.2.  Market analysis, by country

5.3.  API manufacturing

5.3.1.  Market size and forecast
5.3.2.  Market analysis, by country

CHAPTER 6:  PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER

6.1.  Overview

6.1.1.  Market size and forecast

6.2.  Pharmaceutical companies

6.2.1.  Market size and forecast
6.2.2.  Market analysis, by country

6.3.  Contract manufacturing organizations

6.3.1.  Market size and forecast
6.3.2.  Market analysis, by country

6.4.  Others

6.4.1.  Market size and forecast
6.4.2.  Market analysis, by country

CHAPTER 7:  PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION

7.1.  Overview

7.1.1.  Market size and forecast

7.2.  North America

7.2.1.  Key market trends, growth factors, and opportunities
7.2.2.  Market size and forecast, by country

7.2.2.1.  U.S.

7.2.2.1.1.  U.S. pharmaceutical continuous manufacturing market, by product
7.2.2.1.2.  U.S. pharmaceutical continuous manufacturing market, by application
7.2.2.1.3.  U.S. pharmaceutical continuous manufacturing market, by end user

7.2.2.2.  Canada

7.2.2.2.1.  Canada pharmaceutical continuous manufacturing market, by product
7.2.2.2.2.  Canada pharmaceutical continuous manufacturing market, by application
7.2.2.2.3.  Canada pharmaceutical continuous manufacturing market, by end user

7.2.2.3.  Mexico

7.2.2.3.1.  Mexico pharmaceutical continuous manufacturing market, by product
7.2.2.3.2.  Mexico pharmaceutical continuous manufacturing market, by application
7.2.2.3.3.  Mexico pharmaceutical continuous manufacturing market, by end user

7.2.3.  North America market size and forecast, by product
7.2.4.  North America market size and forecast, by application
7.2.5.  North America market size and forecast, by end user

7.3.  Europe

7.3.1.  Key market trends, growth factors, and opportunities
7.3.2.  Market size and forecast, by country

7.3.2.1.  Germany

7.3.2.1.1.  Germany pharmaceutical continuous manufacturing market, by product
7.3.2.1.2.  Germany pharmaceutical continuous manufacturing market, by application
7.3.2.1.3.  Germany pharmaceutical continuous manufacturing market, by end user

7.3.2.2.  France

7.3.2.2.1.  France pharmaceutical continuous manufacturing market, by product
7.3.2.2.2.  France pharmaceutical continuous manufacturing market, by application
7.3.2.2.3.  France pharmaceutical continuous manufacturing market, by end user

7.3.2.3.  UK

7.3.2.3.1.  UK pharmaceutical continuous manufacturing market, by product
7.3.2.3.2.  UK pharmaceutical continuous manufacturing market, by application
7.3.2.3.3.  UK pharmaceutical continuous manufacturing market, by end user

7.3.2.4.  Italy

7.3.2.4.1.  Italy pharmaceutical continuous manufacturing market, by product
7.3.2.4.2.  Italy pharmaceutical continuous manufacturing market, by application
7.3.2.4.3.  Italy pharmaceutical continuous manufacturing market, by end user

7.3.2.5.  Rest of Europe

7.3.2.5.1.  Rest of Europe pharmaceutical continuous manufacturing market, by product
7.3.2.5.2.  Rest of Europe pharmaceutical continuous manufacturing market, by application
7.3.2.5.3.  Rest of Europe pharmaceutical continuous manufacturing market, by end user

7.3.3.  Europe Market size and forecast, by product
7.3.4.  Europe Market size and forecast, by application
7.3.5.  Europe Market size and forecast, by end user

7.4.  Asia-Pacific

7.4.1.  Key market trends, growth factors, and opportunities
7.4.2.  Market size and forecast, by country

7.4.2.1.  Japan

7.4.2.1.1.  Japan pharmaceutical continuous manufacturing market, by product
7.4.2.1.2.  Japan pharmaceutical continuous manufacturing market, by application
7.4.2.1.3.  Japan pharmaceutical continuous manufacturing market, by end user

7.4.2.2.  China

7.4.2.2.1.  China pharmaceutical continuous manufacturing market, by product
7.4.2.2.2.  China pharmaceutical continuous manufacturing market, by application
7.4.2.2.3.  China pharmaceutical continuous manufacturing market, by end user

7.4.2.3.  India

7.4.2.3.1.  India pharmaceutical continuous manufacturing market, by product
7.4.2.3.2.  India pharmaceutical continuous manufacturing market, by application
7.4.2.3.3.  India pharmaceutical continuous manufacturing market, by end user

7.4.2.4.  Rest of Asia-Pacific

7.4.2.4.1.  Rest of Asia-Pacific pharmaceutical continuous manufacturing market, by product
7.4.2.4.2.  Rest of Asia-Pacific pharmaceutical continuous manufacturing market, by application
7.4.2.4.3.  Rest of Asia-Pacific pharmaceutical continuous manufacturing market, by end user

7.4.3.  Asia-Pacific market size and forecast, by product
7.4.4.  Asia-Pacific Market size and forecast, by application
7.4.5.  Asia-Pacific Market size and forecast, by end user

7.5.  LAMEA

7.5.1.  Key market trends, growth factors, and opportunities
7.5.2.  Market size and forecast, by country

7.5.2.1.  Brazil

7.5.2.1.1.  Brazil pharmaceutical continuous manufacturing market, by product
7.5.2.1.2.  Brazil pharmaceutical continuous manufacturing market, by application
7.5.2.1.3.  Brazil pharmaceutical continuous manufacturing market, by end user

7.5.2.2.  South Africa

7.5.2.2.1.  South Africa pharmaceutical continuous manufacturing market, by product
7.5.2.2.2.  South Africa pharmaceutical continuous manufacturing market, by application
7.5.2.2.3.  South Africa pharmaceutical continuous manufacturing market, by end user

7.5.2.3.  Saudi Arabia

7.5.2.3.1.  Saudi Arabia pharmaceutical continuous manufacturing market, by product
7.5.2.3.2.  Saudi Arabia pharmaceutical continuous manufacturing market, by application
7.5.2.3.3.  Saudi Arabia pharmaceutical continuous manufacturing market, by end user

7.5.2.4.  Rest of LAMEA

7.5.2.4.1.  Rest of LAMEA pharmaceutical continuous manufacturing market, by product
7.5.2.4.2.  Rest of LAMEA pharmaceutical continuous manufacturing market, by application
7.5.2.4.3.  Rest of LAMEA pharmaceutical continuous manufacturing market, by end user

7.5.3.  LAMEA market size and forecast, by product
7.5.4.  LAMEA Market size and forecast, by application
7.5.5.  LAMEA Market size and forecast, by end user

CHAPTER 8:  COMPANY PROFILES

8.1.  Coperion GmbH

8.1.1.  Company overview
8.1.2.  Company snapshot
8.1.3.  Operating business segments
8.1.4.  Product Portfolio
8.1.5.  Key strategic moves and developments

8.2.  GEA Group AG

8.2.1.  Company overview
8.2.2.  Company snapshot
8.2.3.  Operating business segments
8.2.4.  Product Portfolio
8.2.5.  Business performance

8.3.  GEBRÜDER LÖDIGE MASCHINENBAU GMBH

8.3.1.  Company overview
8.3.2.  Company snapshot
8.3.3.  Operating business segments
8.3.4.  Product Portfolio

8.4.  Glatt GmbH

8.4.1.  Company overview
8.4.2.  Company snapshot
8.4.3.  Operating business segments
8.4.4.  Product Portfolio

8.5.  Hosokawa Micron Corporation

8.5.1.  Company overview
8.5.2.  Company snapshot
8.5.3.  Product portfolio
8.5.4.  Business performance

8.6.  KORSCH AG

8.6.1.  Company overview
8.6.2.  Company snapshot
8.6.3.  Operating business segments
8.6.4.  Product Portfolio

8.7.  L.B. Bohle Maschinen + Verfahren GmbH

8.7.1.  Company overview
8.7.2.  Company snapshot
8.7.3.  Operating business segments
8.7.4.  Product Portfolio

8.8.  Munson Machinery Company, Inc.

8.8.1.  Company overview
8.8.2.  Company snapshot
8.8.3.  Operating business segments
8.8.4.  Product portfolio

8.9.  Robert Bosch Packaging Technology GmbH

8.9.1.  Company overview
8.9.2.  Company snapshot
8.9.3.  Operating business segments
8.9.4.  Product Portfolio
8.9.5.  Business performance

8.10.  Thermo Fisher Scientific, Inc.

8.10.1.  Company overview
8.10.2.  Company snapshot
8.10.3.  Operating business segments
8.10.4.  Product Portfolio
8.10.5.  Business performance

LIST OF TABLES

TABLE 01.  GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026 ($MILLION)
TABLE 02.  INTEGRATED CONTINUOUS SYSTEMS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03.  SEMI-CONTINUOUS SYSTEMS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04.  OTHERS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05.  GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 06.  FINAL DRUG PRODUCT MANUFACTURING MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.  API MANUFACTURING MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08.  GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 09.  PHARMACEUTICAL CONTINUOUS MANUFACTURING FOR PHARMACEUTICAL COMPANIES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10.  PHARMACEUTICAL CONTINUOUS MANUFACTURING FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018–2026 ($MILLION)
TABLE 11.  PHARMACEUTICAL CONTINUOUS MANUFACTURING FOR OTHERS, BY REGION, 2018–2026 ($MILLION)
TABLE 12.  PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET REVENUE, BY REGION, 2018–2026 ($MILLION)
TABLE 13.  NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 14.  U.S. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 15.  U.S. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 16.  U.S. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 17.  CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 18.  CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 19.  CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 20.  MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 21.  MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 22.  MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 23.  NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 24.  NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 25.  NORTH AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 26.  EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 27.  GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 28.  GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 29.  GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 30.  FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 31.  FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 32.  FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 33.  UK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 34.  UK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 35.  UK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 36.  ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 37.  ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 38.  ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 39.  REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 40.  REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 41.  REST OF EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 42.  EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 43.  EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 44.  EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 45.  ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 46.  JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 47.  JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 48.  JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 49.  CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 50.  CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 51.  CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 52.  INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 53.  INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 54.  INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 55.  REST OF ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 56.  REST OF ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 57.  REST OF ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 58.  ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 59.  ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 60.  ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 61.  LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 62.  BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 63.  BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 64.  BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 65.  SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 66.  SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 67.  SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 68.  SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 69.  SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 70.  SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 71.  REST OF LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 72.  REST OF LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 73.  REST OF LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 74.  LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2018–2026
TABLE 75.  LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2018–2026
TABLE 76.  LAMEA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END USER, 2018–2026
TABLE 77.  COPERION: COMPANY SNAPSHOT
TABLE 78.  COPERION: BUSINESS SEGMENT
TABLE 79.  GEA GROUP: COMPANY SNAPSHOT
TABLE 80.  GEA GROUP: OPERATING SEGMENTS
TABLE 81.  GEA GROUP: PRODUCT PORTFOLIO
TABLE 82.  LÖDIGE: COMPANY SNAPSHOT
TABLE 83.  LÖDIGE: OPERATING SEGMENTS
TABLE 84.  LÖDIGE: PRODUCT PORTFOLIO
TABLE 85.  GLATT: COMPANY SNAPSHOT
TABLE 86.  GLATT: OPERATING SEGMENTS
TABLE 87.  GLATT: PRODUCT PORTFOLIO
TABLE 88.  HOSOKAWA: COMPANY SNAPSHOT
TABLE 89.  HOSOKAWA: PRODUCT PORTFOLIO
TABLE 90.  KORSCH: COMPANY SNAPSHOT
TABLE 91.  KORSCH: OPERATING SEGMENTS
TABLE 92.  KORSCH: PRODUCT PORTFOLIO
TABLE 93.  L.B. BOHLE: COMPANY SNAPSHOT
TABLE 94.  L.B. BOHLE: OPERATING SEGMENTS
TABLE 95.  MUNSON: COMPANY SNAPSHOT
TABLE 96.  L.B. BOHLE: OPERATING PRODUCT SEGMENTS
TABLE 97.  MUNSON: PRODUCT PORTFOLIO
TABLE 98.  BOSCH GROUP: COMPANY SNAPSHOT
TABLE 99.  BOSCH GROUP: OPERATING SEGMENTS
TABLE 100.  BOSCH GROUP: PRODUCT PORTFOLIO
TABLE 101.  THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 102.  THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 103.  THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.  GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SEGMENTATION
FIGURE 02.  TOP INVESTMENT POCKETS, 2018
FIGURE 03.  MARKET PLAYER POSITIONING, 2018
FIGURE 04.  IMPACT ANALYSIS
FIGURE 05.  COMPARATIVE ANALYSIS OF INTEGRATED CONTINUOUS SYSTEMS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 06.  COMPARATIVE ANALYSIS OF SEMI-CONTINUOUS SYSTEMS MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 07.  COMPARATIVE ANALYSIS OF CONTROL & SOFTWARE MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 08.  COMPARATIVE ANALYSIS OF FINAL DRUG PRODUCT MANUFACTURING MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 09.  COMPARATIVE ANALYSIS OF API MANUFACTURING MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10.  COMPARATIVE ANALYSIS OF PHARMACEUTICAL CONTINUOUS MANUFACTURING FOR PHARMACEUTICAL COMPANIES MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11.  COMPARATIVE ANALYSIS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET FOR CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12.  COMPARATIVE ANALYSIS OF PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13.  NET SALES, 2016–2018 ($MILLION)
FIGURE 14.  GEA GROUP: NET SALES BY SEGMENT, 2018 (%)
FIGURE 15.  GEA GROUP: NET SALES BY REGION, 2018 (%)
FIGURE 16.  NET SALES, 2016–2018 ($MILLION)
FIGURE 17.  HOSOKAWA: NET SALES BY SEGMENT, 2018 (%)
FIGURE 18.  HOSOKAWA: NET SALES BY GEOGRAPHY, 2018 (%)
FIGURE 19.  NET SALES, 2016–2018 ($MILLION)
FIGURE 20.  BOSCH GROUP: NET SALES BY SEGMENT, 2018 (%)
FIGURE 21.  BOSCH GROUP: NET SALES BY REVENUE, 2018 (%)
FIGURE 22.  THERMO FISHER SCIENTIFIC: REVENUE, 2016–2018 ($MILLION)
FIGURE 23.  THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 24.  THERMO FISHER SCIENTIFIC: REVENUE SHARE, BY REGION, 2018 (%) 

 
 

Continuous manufacturing is advanced manufacturing approach to provide pharmaceutical products with improved yield within shorter time period.   

Development of the pharmaceutical industry and improvement in productivity of pharmaceuticals with reduced costs are key factors that driving the growth of Pharmaceutical Continuous Manufacturing Market. In addition, initiatives taken by the U.S. FDA for promoting the use of pharmaceutical manufacturing systems for modernizing pharmaceutical manufacturing process and advantage over the batch manufacturing are the major factors that boost the growth of the global market. However, high cost of pharmaceutical continuous manufacturing is a key factor, which hinder the market growth.        

North America is expected to remain dominant during the forecast period due to higher adoption of pharmaceutical continuous manufacturing systems, large presence of pharmaceutical companies, availability of advanced pharmaceutical continuous manufacturing systems, and supportive government policies for adoption of continuous manufacturing. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to increase in adoption of pharmaceutical continuous manufacturing systems along with rise in presence of key pharmaceutical companies in Asia-Pacific.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Pharmaceutical Continuous Manufacturing Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts